Synergistic Antitumor and Apoptotic Activity of Sitagliptin or Linagliptin Plus Cisplatin Against A549 Lung Cancer Cells (an Invitro Study)
DOI:
https://doi.org/10.22317/jcms.v10i3.1555Keywords:
Antitumor, A549 cell line, sitagliptin, linagliptin, MTT assayAbstract
Objective: Lung cancer (LC) has the highest mortality rate globally. Most chemotherapeutic medicines now in use are cytotoxic, prompting the search for novel compounds with anticancer properties and improved safety profiles for normal cells. Dipeptidyl peptidase-4 inhibitors have demonstrated anticancer effects and apoptotic properties by specifically inhibiting dipeptidyl peptidase -4, a glycoprotein found in various organs that support the spread of cancer and tumor formation.
Based on that, this study aimed to evaluate the cytotoxicity and apoptotic activity of sitagliptin (SITA) and linagliptin (LINA) against the lung cancer cell line (A549) alone and in combination with cisplatin (CP).
Methods: A549 cells were categorized into six groups: control (untreated cells), CP-treated cells, SITA-treated cells, LINA-treated cells, CP plus SITA treated cells (1:1 ratio), and CP plus LINA treated cells (1:1 ratio). After 72 hours of incubation, cell viability (or cytotoxicity) and concentration required to inhibit 50% of cell viability (IC50) for each group were determined using an MTT assay. This method is safe and easy to use, has more reproducibility, and is commonly used for cell viability and cytotoxicity tests. Later, A549 cells were cultured in six flasks and exposed to the IC50 for 36 hours. Afterward, the cells were harvested and centrifuged, and the supernatant was removed. The remaining cell pellets were collected and lysed using a lysis buffer to measure B-cell lymphoma type 2 (BCL-2) levels with ELISA test kits. The data was collected and subjected to statistical analysis techniques.
Results: MTT assay results determined that SITA and LINA significantly increased A549 cell cytotoxicity compared to the control group (P<0.0001). Moreover, combining SITA or LINA with CP showed markedly increased antitumor efficacy and more significant cytotoxicity directed toward A549 cells. Additionally, these combinations highly reduced IC50 in comparison to monotherapy. Considerably, both drugs showed remarkable apoptotic activity on A549 cells when used alone or combined with CP by decreasing BCL2 levels. Consequently, it potentiates apoptotic effects and cytotoxicity of CP against cancer cells. Interestingly, Lina was more potent than Sita regarding cytotoxicity and apoptotic activity on A549 cells.
Conclusion: SITA and Lina exhibited significant cytotoxic and apoptotic effects against A549 cells through the induction of apoptosis. Notably, the results suggest a potential synergistic anticancer impact on CP.
References
Al-Tariahi KMJ, Hameed WS, Abdul DH, Saheb AM. Evaluation of CA125 as A
Marker in Patients with Lung Carcinoma. 2015;
Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J,
et al. Metastatic sites and survival in lung cancer. Lung cancer. 2014;86(1):78–84.
Benitez Majano S, Ellis L, Rachet B. Epidemiology of Lung Cancer. Encycl Respir Med Second Ed. 2022 Jan 1;4:663–72.
Chaitanya Thandra K, Barsouk A, Saginala K, Sukumar Aluru J, Barsouk A. Epidemiology of lung cancer. Współczesna Onkol [Internet]. 2021;25(1):45–52. Available from: https://www.termedia.pl/doi/10.5114/wo.2021.103829
Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563–79.
Reck M, Rabe KF. Precision diagnosis and treatment for advanced non–small-cell lung cancer. N Engl J Med. 2017;377(9):849–61.
Brown A, Kumar S, Tchounwou PB. Cisplatin-Based Chemotherapy of Human Cancers. [Internet]. Vol. 11, Journal of cancer science & therapy. 2019. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32148661%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7059781
Tchounwou PB, Dasari S, Noubissi FK, Ray P, Kumar S. Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy. J Exp Pharmacol. 2021;303–28.
Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–78.
Aldossary SA. Review on the pharmacology of cisplatin: clinical use, toxicity and mechanism of cisplatin resistance. Biomed Pharmacol J. 2019;12(1):7–15.
Singh L, Aldosary S, Saeedan AS, Ansari MN, Kaithwas G. Prolyl hydroxylase 2: a promising target to inhibit hypoxia-induced cellular metabolism in cancer cells. Drug Discov Today. 2018;23(11):1873–82.
Gilbert MP, Pratley RE. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Vol. 11, Frontiers in Endocrinology. 2020.
Holst JJ, Gasbjerg LS, Rosenkilde MM. The role of incretins on insulin function and glucose homeostasis. Endocrinology. 2021;162(7):bqab065.
Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Vol. 49, Diabetologia. 2006. p. 2564–71.
Pro B, Dang NH. CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol. 2004 Oct;19(4):1345–51.
Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci. 2008;13(1634):45.
Femia A Pietro, Raimondi L, Maglieri G, Lodovici M, Mannucci E, Caderni G. Long‐term treatment with Sitagliptin, a dipeptidyl peptidase‐4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1, 2‐dimethylhydrazine‐induced rats. Int J cancer. 2013;133(10):2498–503.
Lam CSC, Cheung AHK, Wong SKM, Wan TMH, Ng L, Chow AKM, et al. Prognostic significance of CD26 in patients with colorectal cancer. PLoS One. 2014;9(5):e98582.
Javidroozi M, Zucker S, Chen WT. Plasma seprase and DPP4 levels as markers of disease and prognosis in cancer. Dis Markers. 2012;32(5):309–20.
Boccardi V, Marano L, Rossetti RRA, Rizzo MR, di Martino N, Paolisso G. Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker. BMC Cancer. 2015;15(1):1–6.
Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13(15):1899–911.
Gao Q, Yang S, Kang MQ. Influence of survivin and Bcl-2 expression on the biological behavior of non-small cell lung cancer. Mol Med Rep[Internet]. 2012;5(6):1409–14. Available from: https://doi.org/10.3892/mmr.2012.840
Yang Y, Zhu J, Gou H, Cao D, Jiang M, Hou M. Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC). Med Oncol. 2011;28:796–803.
Amritha CA, Kumaravelu P, Chellathai DD. Evaluation of Anti Cancer Effects of DPP-4 Inhibitors in Colon Cancer- An Invitro Study. J Clin Diagn Res. 2015 Dec;9(12): FC14-6.
Tseng CH. Sitagliptin may reduce breast cancer risk in women with type 2 diabetes. Clin Breast Cancer. 2017;17(3):211–8.
Tseng CH. Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes. Oncotarget. 2017;8(12):19057.
Kabel AM, Atef A, Estfanous RS. Ameliorative potential of sitagliptin and/or resveratrol on experimentally-induced clear cell renal cell carcinoma. Biomed Pharmacother Biomed Pharmacother. 2017;97:667–74.
Bishnoi R, Hong Y, Shah C, Ali A, Skelton IV WP, Huo J, et al. Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study. Cancer Med. 2019;8(8): 3918–27.
Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987;47(4):936–42.
Van Meerloo J, Kaspers GJL, Cloos J. Cell sensitivity assays: the MTT assay. Cancer cell Cult methods Protoc. 2011;237–45.
Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21(9):3233.
Kim K, Kim S, Yu S, Park S, Choi H, Yu H, et al. Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug-resistant MCF-7/MDR human breast cancer cells via decreased doxorubicin efflux. Mol Med Rep. 2015;12(2):1898–904.
Nakashima T, Nagano S, Setoguchi T, Sasaki H, Saitoh Y, Maeda S, et al. Tranilast enhances the effect of anticancer agents in osteosarcoma. Oncol Rep. 2019;42(1):176–88.
Jin X, Wei Y, Liu Y, Lu X, Ding F, Wang J, et al. Resveratrol promotes sensitization to Doxorubicin by inhibiting epithelial‐mesenchymal transition and modulating the SIRT1/β‐catenin signaling pathway in breast cancer. Cancer Med. 2019;8(3):1246–57.
Jang JH, Janker F, De Meester I, Arni S, Borgeaud N, Yamada Y, et al. The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity. Carcinogenesis. 2019;40(2):324–34.
Varela‐Calviño R, Rodríguez‐Quiroga M, Dias Carvalho P, Martins F, Serra‐Roma A, Vázquez‐Iglesias L, et al. The mechanism of sitagliptin inhibition of colorectal cancer cell lines’ metastatic functionalities. IUBMB Life. 2021;73(5):761–73.
Li Y, Li Y, Li D, Li K, Quan Z, Wang Z, et al. Repositioning of Hypoglycemic Drug Linagliptin for Cancer Treatment. Vol. 11, Frontiers in Pharmacology. 2020.
Koehler JA, Kain T, Drucker DJ. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology. 2011;152(9):3362–72.
Wang G, Reed E, Li QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer. Oncol Rep. 2004;12(5):955–65.
Liu H, Yin J, Wang C, Gu Y, Deng M, He Z. FOXO3a mediates the cytotoxic effects of cisplatin in lung cancer cells. Anticancer Drugs [Internet]. 2014;25(8). Available from: https://journals.lww.com/anti-cancerdrugs/fulltext/2014/09000/foxo3a_mediates_the_cytotoxic_effects_of_cisplatin.5.aspx
Kosowska A, Garczorz W, Kłych-Ratuszny A, Aghdam MRF, Kimsa-Furdzik M, Simka-Lampa K, et al. Sitagliptin modulates the response of ovarian cancer cells to chemotherapeutic agents. Int J Mol Sci. 2020;21(23):1–13.
Nachmias B, Ashhab Y, Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. In: Seminars in cancer biology. Elsevier; 2004. p. 231–43.
Letai A. Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest. 2005;115(10):2648–55.
Losert D, Pratscher B, Soutschek J, Geick A, Vornlocher HP, Müller M, et al. Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin but not to docetaxel. Anticancer Drugs [Internet]. 2007;18(7). Available from: https://journals.lww.com/anti-cancerdrugs/fulltext/2007/08000/bcl_2_downregulation_sensitizes_nonsmall_cell_lung.2.aspx
You F, Li C, Zhang S, Zhang Q, Hu Z, Wang Y, et al. Sitagliptin inhibits the survival, stemness, and autophagy of glioma cells and enhances temozolomide cytotoxicity. Biomed Pharmacother. 2023;162:114555.
Mani RJ, Anand M, Agarwal K, Tiwari A, Amanur Rahman Hashmi Q, Vikram Singh T, et al. A Systematic Review of Molecular Pathway Analysis of Drugs for Potential Use in Liver Cancer Treatment. Drugs Drug Candidates [Internet]. 2023;2(2):210–31. Available from: https://www.mdpi.com/2813-2998/2/2/13
Alameen R, Bairam A, Al-Haddad M. Antioxidant and apoptotic activities of sitagliptin against hepatocellular carcinoma: An in vitro study [version 1; peer review: 1 approved with reservations]. F1000Research. 2023;12(962).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
